Dr Reddy's: margin recovery in focus as semaglutide relaunch nears
FROM THE WIRE · GURUFOCUS.COM
Consolidated Revenue: INR8,671 crore (USD905 million), down 1.5% YoY, up 7.4% QoQ.Gross Profit Margin: 52.1%, up 562 bps QoQ, down 254 bps YoY; Global Generics
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralQuarterly results show margin recovery, relevant for expectations on the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Consolidated revenue is INR8,671 crore (USD905 million), down 1.5% YoY and up 7.4% QoQ.
- 02Gross profit margin is 52.1%, up 562 bps QoQ and down 254 bps YoY.
- 03The call highlights margin recovery as the semaglutide relaunch nears.